Last Updated: June 25, 2026

RALTEGRAVIR Drug Patent Profile

Name: RALTEGRAVIR Drug Patent, Exclusivity, and Generic Launch Dataset
Creator: DrugPatentWatch
License: https://www.drugpatentwatch.com/terms.php

✉ Email this page to a colleague

« Back to Dashboard

Which patents cover Raltegravir, and what generic alternatives are available?

Raltegravir is a drug marketed by Hetero Labs Ltd Iii and Lupin and is included in two NDAs.

The generic ingredient in RALTEGRAVIR is raltegravir potassium. There are five drug master file entries for this compound. Four suppliers are listed for this compound. Additional details are available on the raltegravir potassium profile page.

DrugPatentWatch^® Litigation and Generic Entry Outlook for Raltegravir

A generic version of RALTEGRAVIR was approved as raltegravir potassium by LUPIN on May 6^th, 2025.

Start Trial

AI Deep Research

Questions you can ask:

What is the 5 year forecast for RALTEGRAVIR?
What are the global sales for RALTEGRAVIR?
What is Average Wholesale Price for RALTEGRAVIR?

Summary for RALTEGRAVIR

US Patents:	0
Applicants:	2
NDAs:	2
DailyMed Link:	RALTEGRAVIR at DailyMed

Drug patent expirations by year for RALTEGRAVIR

US Patents and Regulatory Information for RALTEGRAVIR

+ Get email alerts for changes to this table

Glossary

Subscribe to access the full database, or Start Trial
Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Hetero Labs Ltd Iii	RALTEGRAVIR POTASSIUM	raltegravir potassium	TABLET;ORAL	203540-001	Dec 19, 2024		DISCN	No	No	⤷ Start Trial	⤷ Start Trial				⤷ Start Trial
Lupin	RALTEGRAVIR POTASSIUM	raltegravir potassium	TABLET;ORAL	217990-001	May 6, 2025	AB	RX	No	No	⤷ Start Trial	⤷ Start Trial				⤷ Start Trial
>Applicant	>Tradename	>Generic Name	>Dosage	>NDA	>Approval Date	>TE	>Type	>RLD	>RS	>Patent No.	>Patent Expiration	>Product	>Substance	>Delist Req.	>Exclusivity Expiration

DrugChatter Q&A for RALTEGRAVIR

Raltegravir patent expiry?
Raltegravir potassium api?

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. We do not provide individual investment advice. This service is not registered with any financial regulatory agency. The information we publish is educational only and based on our opinions plus our models. By using DrugPatentWatch you acknowledge that we do not provide personalized recommendations or advice. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.